Deep vein thrombosis derivatives

Anact C - Human plasma-derived activated Deep vein thrombosis, pulmonary... 

THROMBATE III (Bayer) is a plasma-derived product that is used to treat AT-III deficiency, the first inherited trait discovered which was identified in 1965. The condition is associated with thrombophilia caused by low levels of AT-III or the presence of altered AT-III activity. Both conditions can result in excessive blood clotting. Acquired AT-III deficiency is another condition that occurs in situations with high risk of thrombosis such as trauma, burns, and sepsis. GTG Biotherapeutics conducted chnical trials with ATryn in high-risk situations such as surgery or child de-Hvery to prevent deep-vein thrombosis in hereditary AT-III-deficient patients and heparin-resistant patients with acquired AT-III deficiency undergoing coronary bypass. A pharmacokinetic study in patients with hereditary AT-III deficiency indicated that the administration of the recombinant product resulted in an increase in blood... 

The most frequently reported adverse events are headache, polycythemia, tiredness, common cold, diarrhea, nausea, stomach pains, chest pressure sensation, back pain, leg pain, and dizziness, as confirmed in a phase I open bioequivalence parallel group study of two recombinant human epoetin alfa products the pattern of the adverse events revealed no relevant differences between the erythropoietin derivatives [95 ]. Patients who were randomized to early intervention with immediate epoetin alfa (n = 68) or to standard intervention with epoetin alfa (n = 68), and a further 50 who were not randomized, pain, injection-site pain, bone pain, and deep vein thrombosis were observed [96 ]. 

---